Coherus wins FDA approval for second Lucentis biosimilar, its third drug

Coherus wins FDA approval for second Lucentis biosimilar, its third drug

Submitted by admin on August 3, 2022 - 9:26pm
Source: 
BioPharma Dive
News Tags: 
Coherus Biosciences
biosimilars
Lucentis
Roche
Cimerli
Headline: 
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
snippet: 

Coherus BioSciences will have an edge as it moves to market the second copycat version of the top-selling eye medication Lucentis.

Do Not Allow Advertisers to Use My Personal information